A life-threatening ruxolitinib discontinuation syndrome

被引：40

作者：

Coltro, Giacomo ^{[1
,2
,3
]}

Mannelli, Francesco ^{[1
]}

Guglielmelli, Paola ^{[1
,2
]}

Pacilli, Annalisa ^{[1
,2
]}

Bosi, Alberto ^{[3
]}

Vannucchi, Alessandro Maria ^{[1
,2
,3
]}

机构：

[1] Azienda Osped Univ Careggi, CRIMM, Florence, Italy

[2] Univ Florence, Dept Expt & Clin Med, DenoThe Excellence Ctr, Florence, Italy

[3] Azienda Osped Univ Careggi, Hematol Unit, Florence, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2017年 / 92卷 / 08期

关键词：

POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; MYELOID METAPLASIA; MYELOFIBROSIS; PATHOGENESIS; INHIBITOR; NEOPLASMS; THERAPY; JAK2;

D O I：

10.1002/ajh.24775

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：833 / 838

页数：6

共 18 条

[1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[2] Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) [J].

Barbui, Tiziano ;

Finazzi, Guido ;

Carobbio, Alessandra ;

Thiele, Juergen ;

Passamonti, Francesco ;

Rumi, Elisa ;

Ruggeri, Marco ;

Rodeghiero, Francesco ;

Randi, Maria Luigia ;

Bertozzi, Irene ;

Gisslinger, Heinz ;

Buxhofer-Ausch, Veronika ;

De Stefano, Valerio ;

Betti, Silvia ;

Rambaldi, Alessandro ;

Vannucchi, Alessandro M. ;

Tefferi, Ayalew .

BLOOD, 2012, 120 (26) :5128-5133

[3] Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation [J].

Beauverd, Yan ;

Samii, Kaveh .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (05) :498-501

[4] Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis [J].

Dai, Tong ;

Friedman, Ellen W. ;

Barta, Stefan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :E430-E432

[5] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].

Harrison, Claire ;

Kiladjian, Jean-Jacques ;

Al-Ali, Haifa Kathrin ;

Gisslinger, Heinz ;

Waltzman, Roger ;

Stalbovskaya, Viktoriya ;

McQuitty, Mari ;

Hunter, Deborah S. ;

Levy, Richard ;

Knoops, Laurent ;

Cervantes, Francisco ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano ;

Barosi, Giovanni .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798

[6]

Herman Derrick D, 2014, Ann Am Thorac Soc, V11, P1145, DOI 10.1513/AnnalsATS.201403-127CC

[7] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[8] Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study [J].

Passamonti, Francesco ;

Griesshammer, Martin ;

Palandri, Francesca ;

Egyed, Miklos ;

Benevolo, Giulia ;

Devos, Timothy ;

Callum, Jeannie ;

Vannucchi, Alessandro M. ;

Sivgin, Serdar ;

Bensasson, Caroline ;

Khan, Mahmudul ;

Mounedji, Nadjat ;

Saydam, Guray .

LANCET ONCOLOGY, 2017, 18 (01) :88-99

[9] JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib [J].

Pieri, Lisa ;

Pancrazzi, Alessandro ;

Pacilli, Annalisa ;

Rabuzzi, Claudia ;

Rotunno, Giada ;

Fanelli, Tiziana ;

Guglielmelli, Paola ;

Fjerza, Rajmonda ;

Paoli, Chiara ;

Verstovsek, Srdan ;

Vannucchi, Alessandro M. .

BLOOD, 2015, 125 (21) :3352-3353

[10] Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms [J].

Quintas-Cardama, Alfonso ;

Vaddi, Kris ;

Liu, Phillip ;

Manshouri, Taghi ;

Li, Jun ;

Scherle, Peggy A. ;

Caulder, Eian ;

Wen, Xiaoming ;

Li, Yanlong ;

Waeltz, Paul ;

Rupar, Mark ;

Burn, Timothy ;

Lo, Yvonne ;

Kelley, Jennifer ;

Covington, Maryanne ;

Shepard, Stacey ;

Rodgers, James D. ;

Haley, Patrick ;

Kantarjian, Hagop ;

Fridman, Jordan S. ;

Verstovsek, Srdan .

BLOOD, 2010, 115 (15) :3109-3117

← 1 2 →